Global Cell Penetrating Peptide Market to Reach $8.40 Billion by 2030 Owing To Increasing Demand for Targeted Drug Delivery Systems | Says Coherent Market Insights

BURLINGAME, Calif., March 11, 2024 /PRNewswire/ -- Coherent Market Insights published a report, titled, Global Cell Penetrating Peptide Market, By Type (Protein Derived CPPs, Synthetic CPPs, Chimeric CPPs), By Application (Drug Delivery, Gene Delivery, Diagnostics, Molecular Imaging, Others), By End User (Biopharmaceutical Companies, Contract Research Organization (CROs)/CDMO, Hospitals and Clinics, Others), and By Geography: Size, Share, Outlook, and Opportunity Analysis, 2023-2030. According to the report, the global cell penetrating peptide market was valued at US$ 2.94 Bn in 2023 and is expected to reach US$ 8.40 Bn by 2030, growing at a compound annual growth rate (CAGR) of 16.2% from 2023 to 2030.

Request Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/6553 

Market Dynamics:

The Cell Penetrating Peptide Market is driven by the increasing demand for targeted drug delivery systems, as these peptides have the ability to penetrate cell membranes and deliver drugs directly to target cells. Additionally, the growing focus on personalized medicine and advancements in peptide synthesis technologies are further fueling market growth.

Global Cell Penetrating Peptide Market Report Coverage

Market Trends:

One key trend in the Cell Penetrating Peptide Market is the rising adoption of cell-penetrating peptides in cancer therapy, as these peptides have shown promising results in delivering anti-cancer drugs directly to tumor cells. Another trend is the increasing research and development activities in the field of peptide therapeutics, which is leading to the development of novel peptide-based drugs with improved efficacy and safety profiles.

Market Opportunities:

The market opportunity lies in the increasing demand for cell penetrating peptides (CPPs) in drug delivery applications. CPPs have emerged as an effective tool for delivering various therapeutic molecules across the cell membrane, thereby enhancing the efficacy of drugs. The use of CPPs in drug delivery has shown promising results in targeting specific cells and tissues, reducing off-target effects, and improving drug bioavailability. As a result, pharmaceutical companies are increasingly incorporating CPPs into their drug development pipelines to improve the delivery of biologics, peptides, and nucleic acids.

Another market opportunity stems from the growing applications of cell penetrating peptides in molecular imaging. CPPs conjugated with imaging probes have been utilized for visualizing and tracking various biological processes in real-time, such as tumor growth, inflammation, and gene expression. The ability of CPPs to penetrate cell membranes and deliver imaging agents directly into cells has revolutionized the field of molecular imaging, enabling researchers and clinicians to obtain detailed insights into disease progression and treatment efficacy. The demand for CPP-based imaging technologies is expected to rise as the need for non-invasive diagnostic tools continues to grow.

Buy this Complete Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/6553 

Recent Developments:

On August 16, 2023, Revance Therapeutics, Inc., a biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had approved the first therapeutic indication for DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia in adults. DAXXIFY, powered by Peptide Exchange Technology, was previously approved by the U.S. FDA for the temporary improvement of glabellar lines (frown lines) in adults in September 2022 and is the first true innovation in neuromodulator product formulation in more than 30 years.

On January 6, 2023, Revance Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) had accepted for review a supplemental biologics license application (sBLA) for DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia in adults, a chronic and debilitating neurologic condition affecting the muscles of the neck.

Key Market Takeaways:

Cell Penetrating Peptide market is anticipated to witness a CAGR of 16.2% during the forecast period 2023-2030, owing to the increasing adoption of CPPs in drug delivery and molecular imaging applications.

On the basis of type, the protein-derived CPPs segment is expected to hold a dominant position, owing to their natural origin and high biocompatibility.

By application, the drug delivery segment is projected to lead the market, driven by the growing demand for targeted drug delivery systems. In terms of end users, biopharmaceutical companies are expected to be the key adopters of CPPs for drug development and research purposes.

North America is anticipated to dominate the market, fueled by the presence of major pharmaceutical companies and research institutions in the region.

Read complete market research report, "Global Cell Penetrating Peptide Market, By Type, By Application, By End User, By Geography, Market Size And Share Analysis - Growth Trends And Forecasts 2023-2030", Published by Coherent Market Insights.

Key players operating in the Cell Penetrating Peptide market include AnaSpec, Peptomyc, BioAlps, Sarepta Therapeutics, Inc., REVANCE THERAPEUTICS, and PolyPeptide Group, among others. These companies are focusing on developing novel CPP-based products and expanding their market presence through collaborations and partnerships.

Market Segmentation:

By Type:

• Protein Derived CPPs
• Synthetic CPPs
• Chimeric CPPs

By Application:

• Drug Delivery
• Gene Delivery
• Diagnostics
• Molecular Imaging
• Others

By End User:

• Biopharmaceutical Companies
• Contract Research Organization (CROs)/CDMO
• Hospitals and Clinics
• Others

By Region:

• • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Middle East & Africa
    • South Africa
    • GCC Countries
    • Rest of Middle East & Africa

Ask for Customization: https://www.coherentmarketinsights.com/insight/request-customization/6553

Find more related trending reports below:

Immune Cell Engineering Market, By Cell Type (T Cells, NK Cells, Dendritic Cells, Tumor Cells, Stem Cells, Others), By Product (Consumables, Instruments, Software), By Disease Indication (Cardiovascular Diseases, Respiratory Diseases, Infectious Diseases, Cancer, Neurological Diseases, Others), By Application (Research Applications, Cell Therapy & Regenerative Medicine, Others), By End User (Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, Academic & Research Institutes, Cell Banks, Others), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Alpha Emitter Market, by Type of Radionuclide (Radium (Ra-223), Actinium (Ac-225), Lead (Pb-212), Astatine-211, Bismuth-213 and Others), by Source (Natural Sources (Uranium-238 and Radium-226) Artificially Produced Sources (Plutonium, Americium, Curium and Californium), by Application (Bone Metastases, Prostate Cancer, Neuroendocrine Tumors, Ovarian Cancer and Others), by End User (Hospitals, Specialty Clinics, Diagnostic Centers and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)

DNA Sequencing Market, by Product Type (Consumables, Instruments, and Services), by Technology (Sanger Sequencing, Next-Generation Sequencing, Third- Generation DNA Sequencing, and Others), by Application (Oncology, Reproductive Health, Clinical Investigation, Agrigenomics & Forensics, Metagenomics, Epidemiology & Drug Development, and Others), by End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Clinical Research, and Others), by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Pruritus Therapeutics Market, by Drug Class (Corticosteroids, Antihistamines, Counterirritants, Immunosuppressant, Calcineurin Inhibitors, and Others), by Indication (Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Psoriasis, and Others), by Route of Administration (Oral, Parenteral, and Topical), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

About Us:

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg